Familial Mediterranean Fever (FMF) – Evidence‑Based Guideline Summary

Epidemiology & Disease Characteristics

FMF is the most common monogenic autoinflammatory disease, characterized by recurrent self‑limited fever and serositis episodes lasting 12–72 hours, and it predominantly affects Mediterranean ethnic groups (Arabs, Armenians, Turks, Jews). 1

Subclinical inflammation may persist between attacks and can be detected by elevated acute‑phase reactants. 2
Laboratory monitoring of acute‑phase reactants (e.g., CRP, SAA) is recommended both during attacks and in asymptomatic periods to identify ongoing inflammation. 2
An annual review by a physician experienced in FMF is advised for optimal long‑term management. 2
Treatment goals for FMF include complete suppression of spontaneous attacks, reduction of subclinical inflammation, and prevention of AA amyloidosis. 2

Immediate initiation of colchicine upon clinical suspicion is recommended to prevent attacks and life‑threatening complications such as AA amyloidosis. 3
Colchicine dosing is weight‑ and age‑adjusted:
- ≤0.5 mg/day for children < 5 years
- 0.5–1.0 mg/day for children 5–10 years
- 1.0–1.5 mg/day for children > 10 years and adults
- Doses may be given as a single or divided administration based on tolerance. [3][4]

Treatment response, toxicity, and adherence should be evaluated at least every six months. 4
If attacks persist or subclinical inflammation remains, the colchicine dose may be increased within the recommended range; temporary dose escalation is appropriate during stress‑related triggers. 4

Patients who remain symptomatic despite the maximum tolerated colchicine dose and confirmed adherence are classified as colchicine‑resistant and should be considered for biologic therapy. 4
IL‑1 inhibitors (e.g., anakinra, canakinumab, rilonacept) are the preferred biologic agents for colchicine‑resistant FMF. 4
In the presence of AA amyloidosis, treatment should be intensified with the highest tolerated colchicine dose combined with biologic agents as required. 4

After initial diagnosis and management by an FMF‑experienced specialist, ongoing care should be coordinated with a general practitioner to ensure continuous monitoring and patient education. 3

Familial Mediterranean Fever (FMF) is characterized by brief, recurring, self-limited episodes of fever accompanied by inflammation of serosal surfaces, resulting in various symptoms 5, 6, 7

Joint pain (arthritis/synovitis) is a common symptom of FMF 5
These attacks typically last 1-3 days and are accompanied by marked elevation of acute phase reactants 5

FMF follows three distinct clinical patterns, each affecting approximately one-third of patients: monocyclic, polycyclic/intermittent, and chronic patterns 8

FMF is the most common monogenic autoinflammatory disease, particularly prevalent in Mediterranean and Middle Eastern populations 5, 6
Diagnosis is primarily clinical, though genetic testing for MEFV gene mutations can confirm the diagnosis 9, 10
Differential diagnosis includes other periodic fever syndromes (TRAPS, hyper-IgD syndrome), infectious diseases, and neoplastic disorders 8

Regular colchicine treatment significantly reduces the risk of amyloidosis from 60% to less than 13% 11
Colchicine is the first-line treatment and should begin immediately upon clinical diagnosis 11
Dosing is weight-based and age-dependent, with specific recommendations for children and adults 11
Regular monitoring of acute phase reactants is necessary even during asymptomatic periods to detect subclinical inflammation 11
Colchicine should be used with caution in patients with renal impairment 12